广东乐心医疗电子股份有限公司 独立董事 2024 年度述职报告 （张昱波） 本人作为广东乐心医疗电子股份有限公司（以下简称"公司"）的独立董 事，任职期间严格按照《公司法》《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 —创业板上市公司规范运作》等相关法律法规和《公司章程》《独立董事工作 制度》等公司相关的规定和要求，认真、勤勉、谨慎履行职责，积极出席相关 会议，对各项议案进行认真审议，对公司重大事项发表了明确意见，不受公司 大股东、实际控制人或者其他与公司存在利害关系的单位与个人的影响，充分 发挥了独立董事及各专门委员会委员的作用。一方面，严格审核公司提交董事 会的相关事项，维护公司和公众股东的合法权益，促进公司规范运作；另一方 面发挥自己的专业优势，积极关注和参与研究公司的发展，为公司的审计、内 控、战略等工作提出了意见和建议。现将本人 2024 年度履行独立董事职责情况 向各位股东汇报如下： 一、个人基本情况 张昱波，男，1981 年出生，中国国籍，无境外永久居留权，硕士研究生。 2006 年 12 月至 2017 年 01 月历任深圳市 ...

广东乐心医疗电子股份有限公司 2024 年年度报告全文 广东乐心医疗电子股份有限公司 2024 年年度报告 1 2025 年 03 月 29 日 广东乐心医疗电子股份有限公司 2024 年年度报告全文 2024 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人潘伟潮、主管会计工作负责人黄林香及会计机构负责人(会计主管人员)汪 小飞声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 2 广东乐心医疗电子股份有限公司 2024 年年度报告全文 本年度报告如有涉及未来计划等前瞻性陈述，均不构成公司对任何投资者及相关人士的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异， 敬请投资者注意投资风险。 可能存在的风险因素 1、公司快速发展带来的管理风险 随着公司逐步发展，资产和业务规模进一步扩大，尽管公司已形成了较为成熟的经营模式，并建立 了相对完善的管理制度、研发体系、营销网 ...

证券代码：300562 证券简称：乐心医疗 公告编号：2025-010 广东乐心医疗电子股份有限公司 关于延续医疗器械注册证获得受理的公告 乐心医疗 2025 年公告 上述胎儿心率记录仪由主机、硅胶套、无线充电器及移动端软件组成，其中 移动端软件由关于模块、用户管理模块、设备管理模块、数据显示模块、数据管 理模块及数据传输模块组成。该产品采用被动式采集胎心音检测，类似听诊器的 被动式原理，外观设计小巧便携，适用于对妊娠 32 周以上单胎孕妇的胎心曲线 记录，提供数据给孕妇，缓解焦虑，提高孕期质量。 公司定位于"医疗级远程健康监测设备及服务提供商"，始终高度重视医疗 器械标准符合性，推动全系列产品向医疗级方向发展。上述医疗器械延续注册符 合公司实际情况，有利于公司进一步开拓业务，增强综合竞争力，对公司经营发 展起到积极作用。上述医疗器械延续注册事宜目前尚处于受理阶段，后续仍需相 关机构进一步核准认证，评审在各阶段所需的时间和结果均具有一定的不确定性。 公司目前尚无法预测其对公司未来业绩的影响，敬请广大投资者注意投资风险。 特此公告。 广东乐心医疗电子股份有限公司 董事会 二〇二五年三月二十六日 本公司及董事会全 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5] Core Views - The company aims to become a global leader in remote health monitoring, leveraging opportunities in the health IoT and digital health services sectors [4] - Revenue projections for 2024-2026 are estimated at 1.025 billion, 1.225 billion, and 1.443 billion yuan, with year-on-year growth rates of 16%, 20%, and 18% respectively [5] - The company has shown significant improvement in profitability, with net profit forecasts for 2024-2026 at 62.18 million, 88.65 million, and 124.03 million yuan, reflecting growth rates of 81%, 43%, and 40% respectively [5] Company Overview - The company was founded in 2002 and has shifted its focus towards smart health, aiming to align with national strategies for "Healthy China" and "Digital China" [18] - The largest shareholder, Pan Weichao, holds 33.14% of the company and has extensive experience in the home medical electronics sector [20] - The company has actively optimized its customer and product structure since 2022, leading to a significant increase in gross margin [21] Financial Performance - In 2023, the company reported a gross margin of 30.94%, up 7.24 percentage points year-on-year, despite a revenue decline of 16.98% [21] - For the first nine months of 2024, revenue reached 755.6 million yuan, a 24.39% increase year-on-year, with net profit at 51 million yuan, up 232.83% [22] Business Segments - The company operates in two main segments: health IoT and digital health services, focusing on medical-grade health IoT devices and remote health management solutions [27] - The health IoT segment includes medical-grade devices and RPM solutions, while the digital health services segment encompasses digital blood pressure management and remote ECG services [27] Product Development - The company has introduced new products such as hearing aids and smart ECG clothing, with the smart ring expected to launch in 2025 [6] - The company has established strong partnerships with leading health IoT companies, enhancing its market presence [35] Market Potential - The global market for home medical devices is projected to grow significantly, with the wearable medical device market in China valued at 22.08 billion yuan in 2023 [34] - The wearable device market is expected to reach 431.74 billion USD by 2034, indicating substantial growth opportunities for the company [41]

证券研究报告：医药生物 | 公司深度报告 2025 年 3 月 14 日 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 15.58 | | --- | --- | | 总股本/流通股本（亿股）2.17 | / 1.61 | | 总市值/流通市值（亿元）34 | / 25 | | 52 周内最高/最低价 | 17.56 / 7.55 | | 资产负债率(%) | 34.2% | | 市盈率 | 97.56 | | 第一大股东 | 潘伟潮 | 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 研究助理:陈峻 SAC 登记编号:S1340123110013 Email:chenjun@cnpsec.com 乐心医疗(300562) 公司医疗垂直领域大模型赋能慢病管理设备，"AI + 可穿戴 + 医疗"有望迎来爆发 l 公司致力于成为"远程健康监测全球领导者" 乐心医疗紧抓健康 IoT 和数字健康服务行业高速发展机遇，积极 顺应"健康中国"和"数字中国"建设国家战略发展方向，凭借多年 在智能健康硬件、大 ...

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-009 广东乐心医疗电子股份有限公司 关于持股5%以上股东减持计划实施完成 暨权益变动触及1%的公告 股东潘伟潮先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于近日收到公司控股 股东、实际控制人潘伟潮先生出具的《持股 5%以上股东减持计划实施完成暨权 益变动触及 1%的告知函》，获悉潘伟潮先生减持计划已实施完成并因实施减持 导致权益变动触及 1%。现将具体情况公告如下： 一、减持计划实施完成相关情况 1、本次减持计划实施情况 2、减持计划实施前后股东持股情况 | 股东名称 | 股份性质 | | 本次减持前持有股份 | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | | | 股数（万股） | 占总股本比例 | 股数（万股） | 占总股本比例 | | 潘伟潮 | 合计持有股份 其 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [4]. Core Views - The strategic transformation of the company is showing significant results, with the AI+ healthcare model expected to reshape the valuation system [2][3]. - The company has focused on high-margin medical-grade remote health monitoring devices and services, leading to improved operational efficiency and profitability [2]. - The company is well-positioned to benefit from the expansion of the chronic disease management market and the emerging AI+ healthcare sector [8]. Financial Summary - Revenue projections for 2024-2026 are estimated at 1.013 billion, 1.266 billion, and 1.585 billion yuan, respectively, with year-over-year growth rates of 14.5%, 25.0%, and 25.2% [1][8]. - The net profit attributable to the parent company is expected to reach 64 million, 105 million, and 145 million yuan for the same period, reflecting year-over-year growth rates of 85.5%, 64.6%, and 38.2% [1][8]. - The company's return on equity (ROE) is projected to improve from 5.5% in 2024 to 10.9% in 2026 [1]. Business Segments - The health equipment segment is focusing on new product launches, including blood glucose meters and hearing aids, which are expected to gain market traction [2]. - The RPM (Remote Patient Monitoring) segment has established deep collaborations with leading clients in Europe and the US, creating a closed-loop business model [2]. - The cardiovascular digital chronic disease service segment is integrating remote health monitoring devices with AI software and medical services, with initial validation in various healthcare settings [2]. Market Position and Future Outlook - The company has accumulated a substantial amount of multi-dimensional physiological data from over ten million users, laying a solid foundation for developing a vertical AI model in the cardiovascular field [3]. - The report anticipates that the company will achieve a revenue of 1.013 billion yuan in 2024, with a corresponding net profit of 0.64 billion yuan, indicating a strong growth trajectory [8].

Summary of Leksun Medical Conference Call Company Overview - Leksun Medical focuses on the AI medical field, particularly in remote devices and services, large models, and artificial intelligence [3] - Established in 2000, Leksun has undergone four development phases, transitioning from low-margin wearable devices to high-margin professional medical products [4][5] Core Business Segments - Leksun Medical operates three main business segments: - Home medical products (over 50% of total revenue, gross margin of 25%-30%) - Digital chronic disease management (over 40% of total revenue, gross margin of 45%-50%) - Innovative business (around 10% of total revenue, gross margin of 40%-50%) [6] Financial Performance and Projections - Leksun expects a net profit margin of 10%-15% and revenue growth of 30%-40% by 2025 [8] - The company achieved over 1.8 billion yuan in revenue in 2021, with a projected net profit of 60-64 million yuan for 2024 [13] AI and Technology Integration - Leksun's AI technology enables continuous monitoring and timely alerts, providing 24-hour personal doctor and health coach services [3] - The company invests over 100 million yuan annually in R&D, accounting for over 10% of commercial revenue, focusing on new product development and technological advancement [14] Market Position and Competitive Advantages - Leksun holds over 70% market share in the digital chronic disease management sector in Europe and the US [4][10] - The company has strong manufacturing capabilities with three production bases in Zhongshan, achieving a total capacity of 4 billion yuan [9] - Leksun has established partnerships with notable companies like Huawei and Teladoc, enhancing its market presence [4][9] Future Strategies - Leksun aims to solidify internal operations while expanding external markets, focusing on cost reduction and efficiency improvement [12] - The company plans to release new products, including rings and medical-grade wearable devices, in 2025 [31] Global Market and User Data - Leksun has over 20 million registered users, providing a substantial data pool for health monitoring and product development [18][19] - The company manages a significant number of patients in the US, with a projected growth rate of over 40% in its RPM business from 2023 to 2024 [27][29] Conclusion - Leksun Medical is positioned for robust growth in the AI medical sector, leveraging its technological advancements, strong market presence, and strategic partnerships to enhance its service offerings and financial performance [3][4][12][27]